KEGG   DRUG: Darunavir and cobicistat
Entry
D10832            Mixture   Drug                                   
Name
Darunavir and cobicistat;
Prezcobix (TN);
Rezolsta (TN)
  Abbr
DRV/c
Product
PREZCOBIX (A-S Medication Solutions), PREZCOBIX (Janssen Products LP)
Component
(Darunavir ethanolate [DR:D06478] | Darunavir [DR:D03656]), Cobicistat [DR:D09881]
Class
Antiviral
 DG03107  Anti-HIV agent
Metabolizing enzyme substrate
 DG01644  CYP2D6 substrate
 DG01633  CYP3A/CYP3A4 substrate
Metabolizing enzyme inhibitor
 DG01645  CYP2D6 inhibitor
 DG02852  CYP3A/CYP3A4 inhibitor
Transporter inhibitor
 DG01622  ABCB1 inhibitor
 DG02862  ABCG2 inhibitor
 DG02865  SLCO1B1 inhibitor
 DG02907  SLCO1B3 inhibitor
Remark
Therapeutic category: 6250
ATC code: J05AR14
Product: D10832<JP/US>
Efficacy
Antiviral
  Disease
HIV-1 infection [DS:H01563]
Comment
Darunavir is a substrate of CYP3A; it is also an inhibitor of CYP3A, CYP2D6 and P-gp.
Cobicistat is metabolized by CYP3A and CYP2D6 and inhibits CYP3A, CYP2D6, P-glycoprotein, BCRP, OATP1B1 and OATP1B3.
Target
HIV protease [KO:K22599]
  Pathway
ko03230  Viral genome structure
ko03250  Viral life cycle - HIV-1
Metabolism
Enzyme: CYP3A [HSA:1576 1577 1551], CYP2D6 [HSA:1565]
Interaction
CYP inhibition: CYP3A [HSA:1576 1577 1551], CYP2D6 [HSA:1565]
Transporter inhibition: ABCB1 [HSA:5243], ABCG2 [HSA:9429], SLCO1B1 [HSA:10599], SLCO1B3 [HSA:28234]
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 J ANTIINFECTIVES FOR SYSTEMIC USE
  J05 ANTIVIRALS FOR SYSTEMIC USE
   J05A DIRECT ACTING ANTIVIRALS
    J05AR Antivirals for treatment of HIV infections, combinations
     J05AR14 Darunavir and cobicistat
      D10832  Darunavir and cobicistat <JP/US>
USP drug classification [BR:br08302]
 Antivirals
  Anti-HIV Combinations
   Cobicistat/ Darunavir
    D10832  Darunavir and cobicistat
Therapeutic category of drugs in Japan [BR:br08301]
 6  Agents against pathologic organisms and parasites
  62  Chemotherapeutics
   625  Antivirals
    6250  Antivirals
     D10832  Darunavir and cobicistat
Drug groups [BR:br08330]
 Antiviral
  DG03107  Anti-HIV agent
   D10832  Darunavir and cobicistat
 Metabolizing enzyme substrate
  DG01644  CYP2D6 substrate
   D10832  Darunavir and cobicistat
  DG01633  CYP3A/CYP3A4 substrate
   D10832  Darunavir and cobicistat
 Metabolizing enzyme inhibitor
  DG01645  CYP2D6 inhibitor
   D10832  Darunavir and cobicistat
  DG02852  CYP3A/CYP3A4 inhibitor
   D10832  Darunavir and cobicistat
 Transporter inhibitor
  DG01622  ABCB1 inhibitor
   D10832  Darunavir and cobicistat
  DG02862  ABCG2 inhibitor
   D10832  Darunavir and cobicistat
  DG02865  SLCO1B1 inhibitor
   D10832  Darunavir and cobicistat
  DG02907  SLCO1B3 inhibitor
   D10832  Darunavir and cobicistat
Drug classes [BR:br08332]
 Antiviral
  DG03107  Anti-HIV agent
   D10832  Darunavir and cobicistat
Antimicrobials [BR:br08307]
 Antivirals
  Polyprotein cleavage inhibitor
   HIV protease inhibitor
    D10832  Darunavir and cobicistat <JP/US>
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D10832
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D10832
 Drug transporters
  D10832
Other DBs
PubChem: 319902632
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system